Vir Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vir Biotechnology, Inc.
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
While Lilly's antibody combination of etesevimab and bamlanivimab is still going strong in the US, the company has lost out to Roche's Ronapreve in the EU.
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
- Large Molecule
- Other Names / Subsidiaries
- Humabs BioMed SA